Company intelligence / Profile preview
Fuzhou Tcelltech Biological Science and Technology Inc.
Fuzhou, Fujian, Chinatcelltech.cn ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Fuzhou Tcelltech is developing TX103, an autologous CAR-T cell therapy targeting B7-H3 for recurrent glioblastoma and high-grade gliomas. Early phase I clinical data presented at ASCO 2024 indicate the company is evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy via intracavity/intraventricular administration in patients with recurrent GBM. The program has orphan drug designation for gliomas. No late-stage or commercial products are reported.
- Therapeutic areas
- Oncology
- Modalities
- Autologous CAR-T cell therapyGene therapiesImmunotherapies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Fuzhou Tcelltech Biological Science and Technology Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fuzhou Tcelltech Biological Science and Technology Inc..